Breaking News

Hospira Acquires Filgrastim Rights and PLIVA Facility

Hospira, Inc. has acquired worldwide rights to a biogeneric version of filgrastim and an affiliated manufacturing facility from PLIVA Hrvatska in Zagreb, Croatia.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira, Inc. has acquired worldwide rights to a biogeneric version of filgrastim and an affiliated manufacturing facility from PLIVA Hrvatska in Zagreb, Croatia. Financial terms were not disclosed. Hospira will now have full global rights to the biogeneric filgrastim that had previously been part of a strategic collaboration between Hospira and PLIVA/Barr, now owned by Teva Pharmaceutical Industries Ltd. As part of the agreement, Hospira has also acquired process development capabilities....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters